Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OPS-2071 in IBS-D
NCT05923892Phase 2Completed
- Sponsor
- Otsuka Holdings
- Start
- Aug 2023
- Primary completion
- Aug 2024
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of OPS-2071 in Irritable bowel syndrome with diarrhea (IBS-D) (4 arms), sponsored by Otsuka Holdings. Primary endpoints: Change from baseline to Week 2 in NRS abdominal pain and Change from baseline to Week 2 in Bristol stool scale. Started Aug 2023; status: completed.
02
Drugs
OPS-2071
03
Conditions
Irritable bowel syndrome with diarrhea (IBS-D)
Beyond the preview
Go deeper on NCT05923892.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05923892.